BOSTON--(BUSINESS WIRE)--DeepCure, a therapeutics company using AI to discover novel drugs for inflammation and immune diseases, today announced it will present data showing its selective BRD4 (BD2) inhibitor DC-9476 is superior to anti-TNF-α treatment in the collagen antibody-induced arthritis (CAIA) rheumatoid arthritis (RA) mouse model at the 11th International Conference on Autoimmunity: Mechanisms and Novel Treatments in Crete, Greece..

波士顿--（商业新闻短讯）--DeepCure是一家利用人工智能发现炎症和免疫疾病新药的治疗公司，今天宣布将提供数据，显示其选择性BRD4（BD2）抑制剂DC-9476优于抗TNF-α治疗胶原抗体诱导的关节炎（CAIA）类风湿性关节炎（RA）小鼠模型在希腊克里特岛举行的第11届国际自身免疫：机制和新疗法会议上。。

Activated macrophages play a central role in the onset and progression of RA. They can produce proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which are responsible for joint damage and symptoms.

。它们可以产生促炎细胞因子，如肿瘤坏死因子-α（TNF-α），白细胞介素-1β（IL-1β）和白细胞介素-6（IL-6），这些细胞因子负责关节损伤和症状。

DC-9476 was evaluated in a series of preclinical studies to investigate its potential as a treatment for RA. Results from an in vitro cell-based assay that stimulated the activation of human macrophage-like cells and IL-6 production demonstrated that DC-9476 decreased IL-6 production and it was more potent than tofacitinib, a currently marketed Jak-2 inhibitor for the treatment of RA..

DC-9476在一系列临床前研究中进行了评估，以研究其作为RA治疗的潜力。刺激人巨噬细胞样细胞活化和IL-6产生的体外基于细胞的测定结果表明，DC-9476降低了IL-6的产生，并且比目前市售的用于治疗RA的Jak-2抑制剂托法替尼更有效。。

The in vivo efficacy of DC-9476 was evaluated using two mouse models. In a lipopolysaccharide (LPS)-induced inflammation model, DC-9476 reduced both serum IL-6 and TNF-α levels. In the CAIA model, which mimics macrophage-driven RA, DC-9476 treatment led to a greater than 80% reduction in the clinical disease score, outperforming etanercept, a currently approved anti-TNF-α antibody, which only achieved a 47% reduction.

使用两种小鼠模型评估DC-9476的体内功效。在脂多糖（LPS）诱导的炎症模型中，DC-9476降低血清IL-6和TNF-α水平。在模拟巨噬细胞驱动的RA的CAIA模型中，DC-9476治疗导致临床疾病评分降低了80%以上，优于依那西普（目前批准的抗TNF-α抗体），依那西普仅降低了47%。

Importantly, DC-9476 showed no signs of toxicity in both models. The combination of DC-9476 and etanercept resulted in significantly greater improvement compared to either treatment alone..

重要的是，DC-9476在两种模型中均未显示毒性迹象。与单独使用任何一种治疗相比，DC-9476和依那西普的组合都能显着改善。。

Details of the presentation:

演示的详细信息：

Poster Title: Novel, Selective BRD4 (BD2) Inhibitor DC-9476 Demonstrates a Potent Anti-inflammatory Mechanism

海报标题：新型选择性BRD4（BD2）抑制剂DC-9476表现出有效的抗炎机制

Date: October 19, 10:25 am (local time)

日期：10月19日上午10:25（当地时间）

Presenter: Dr. Michal Segal-Salto, Senior Director - Biology, DeepCure

“This is the first time we are presenting in vivo data in animal models of RA for DC-9476, which demonstrates its potential as a novel oral monotherapy or combination therapy for patients,” said Kfir Schreiber, CEO & Co-Founder of DeepCure. “In addition, this selective BRD4 (BD2) inhibitor reduced key inflammatory cytokines that could be used as biomarkers of target engagement in future clinical trials.”.

DeepCure首席执行官兼联合创始人Kfir Schreiber表示：“这是我们首次在RA动物模型中提供DC-9476的体内数据，这证明了其作为新型口服单一疗法或患者联合疗法的潜力。”。“此外，这种选择性BRD4（BD2）抑制剂减少了关键的炎性细胞因子，这些细胞因子可以用作未来临床试验中靶标参与的生物标志物。”。

About DeepCure

关于DeepCure

DeepCure is a therapeutics company focused on advancing novel drugs with the potential to transform the treatment of inflammation and autoimmune diseases. The company was founded by researchers at MIT to accelerate breakthrough therapies using artificial intelligence (AI) and AI-enabling technologies for small molecule discovery.

DeepCure是一家治疗公司，专注于开发具有改变炎症和自身免疫性疾病治疗潜力的新药。该公司是由麻省理工学院的研究人员成立的，旨在利用人工智能（AI）和人工智能技术促进小分子发现，加速突破性治疗。

The company is based in Boston, MA, and its engineers, chemists, and biologists collaborate to find solutions to hard problems that will have an enormous impact on patient health. For more information, visit www.deepcure.ai..

该公司总部位于马萨诸塞州波士顿，其工程师、化学家和生物学家合作，寻找对患者健康产生巨大影响的难题的解决方案。有关更多信息，请访问www.deepcure.ai。。